Wezenla

Wezenla is a medicine used to treat: - moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children above the age of 6 years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine called psoralen, before being exposed to ultraviolet light; - active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not improved enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs). Wezenla may be used alone or combined with methotrexate (a DMARD); - moderately to severely active Crohn’s disease (a disease-causing inflammation of the gut) in adults whose condition has not improved enough with other treatments for Crohn’s disease or who cannot receive such treatments. Wezenla contains the active substance ustekinumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Wezenla is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Wezenla is Stelara. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines).